Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia

Objectives: To determine whether drug-induced lymphocytopenia is associated with drug retention rates of JAKi (tofacitinib or baricitinib) in rheumatoid arthritis (RA) patients. Methods: Patients with RA who were initiated with tofacitinib (n = 38) or baricitinib (n = 74) between July 2015 and July 2022 and continued for at least 4 months were enrolled in this study. Absolute lymphocyte count (ALC) value was obtained pre-treatment and monthly after initiation of JAKi (up to 4 months). Associations between ALC nadir at an early phase (up to 4 months) from JAKi initiation and drug retention rates were analysed. Results: 112 patients (87 females; age, 71.2 & PLUSMN; 14.0 years; disease duration, 9.2 & PLUSMN; 10.5 months; DAS28-CRP, 3.60 & PLUSMN; 1.12; DAS28-ESR, 4.43 & PLUSMN; 1.29; CDAI, 17.9 & PLUSMN; 12.9; C-reactive protein, 3.07 & PLUSMN; 3.43 mg/dL; and lymphocyte count, 1361.9 & PLUSMN; 538.7 per & mu;L) treated with tofacitinib or baricitinib were retrospectively analysed. Lymphocytopenia (>10% decline in lymphocyte count to pre-treatment basal levels) was observed in a quarter of RA patients treated with JAKi (tofacitinib; 16 baricitinib; 14). RA patients with lymphopenia were associated with the lower drug retention rates of tofacitinib compared to those without lymphocytopenia. The reduced drug retention rates in patients with lymphocytopenia were attributed to the discontinuation of tofacitinib due to AEs. Whereas lymphocytopenia was not associated with lower drug retention rates of baricitinib. Pre-treatment absolute lymphocyte counts did not affect the drug retention rates of JAKi in patients with RA. Conclusions: These findings suggest that lymphopenia during the first 4 months from the initiation of JAKi is associated with reduced drug retention rates in patients with RA due to AEs, which is exclusively associated with the use of tofacitinib.

Automated summary

This study found that drug-induced lymphocytopenia is associated with reduced drug retention rates of JAK inhibitors (tofacitinib or baricitinib) in rheumatoid arthritis (RA) patients. A quarter of RA patients treated with JAK inhibitors showed lymphocytopenia, which was associated with lower drug retention rates of tofacitinib but not baricitinib. Pre-treatment absolute lymphocyte counts did not affect the drug retention rates of JAK inhibitors in patients with RA.